Infinitopes announced its second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million.
Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).
AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.
Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.
Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.
Relation and healthcare investment firm Deerfield Management, a current investor, has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.
Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.
The first in a new series of skills webinars for the BIA Finance and Tax Community explored some of the most significant milestones in a company’s growth journey, with insights and reflections from experts with firsthand experience.
Our latest TechBio: Future-ready biology report confirms a major structural shift in the UK life sciences sector: TechBio has moved from a niche field to the mainstream, accounting for over 40% of all UK biotech deals in recent years.
In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.
In this blog, Tom Sheldon, Senior Manager at the Science Media Centre (SMC), explores how scientists and communicators are taking on misinformation head-on — and how the SMC’s work supports both researchers and journalists in helping the public make sense of complex, and sometimes controversial, scientific issues.
Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.
Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
Pioneer Group has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.
Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.
